Latest News

Torrent Pharma has launched Adalimumab biosimilar in India

Torrent Pharmaceuticals has launched its biosimilar Adalimumab in India which is used in treating auto immune disorders, under the brand name ‘Adfrar’.

Torrent Pharmaceuticals said in a statement that the company’s product will be available as pre-filled syringe of 40 mg.

The company however did not provide any details regarding the price at which the biosimilar will available.

Torrent Pharmaceuticals said in that Adalimumab is a preferred therapy for the treatment of auto immune disorders and has wide applications for treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, uclerative colitis and plaque psoriasis among others.

It further added that autoimmune disorders are growing ailments and monoclonal antibodies (MAb’s) are becoming mainstay of treatment.

Read EquityPandit’s Nifty Pharma outlook for this week

Click here to check market prediction for next trading session.

Get Daily Prediction & Stocks Tips On Your Mobile


I would like to receive communication from EquityPandit via sms, email, whatsapp, Google RCS for offers, updates etc.



πŸ“°
News
πŸ“ˆ
Prediction
πŸ“Š
FII / DII
πŸ‘”
Advisory
Get 1-2 Index Option Trades Daily